ethosuximide
Brand: Zarontin
TDM Required Prototype Drug
Drug Class: antiepileptic drug
Drug Family: antiepileptic
Subclass: T-type calcium channel blocker — absence seizure specific
Organ Systems: cns
Mechanism of Action
Selectively inhibits T-type Ca2+ channels in thalamic relay neurons, suppressing the rhythmic thalamocortical discharge that is the electrophysiological basis of absence seizures. This mechanism is specific to absence epilepsy and ethosuximide has NO effect on other seizure types.
T-type (transient) voltage-gated Ca2+ channels in thalamic neurons
Indications
- absence epilepsy (ONLY — drug of first choice for pure absence seizures)
Contraindications
- hypersensitivity to succinimide-class AEDs
Adverse Effects
Common
- nausea
- GI upset (take with food)
- drowsiness
- dizziness
- hiccups
- headache
Serious
- blood dyscrasias (aplastic anemia, agranulocytosis — rare but serious)
- SJS (rare)
- psychiatric reactions (agitation, aggression)
Pharmacokinetics (ADME)
| Absorption | oral; bioavailability ~100% |
| Distribution | low protein binding (<10%) |
| Metabolism | hepatic via CYP3A4 and CYP2E1 to inactive metabolites |
| Excretion | renal (20% unchanged; 80% as metabolites) |
| Half-life | 60 hours (adults); 30 hours (children) |
| Onset | days |
| Peak | 1–4 hours |
| Duration | once-daily or BID dosing |
| Protein Binding | <10% |
| Vd | 0.62 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| valproate | valproate inhibits CYP2E1, potentially increasing ethosuximide levels; monitor for toxicity | moderate |
Nursing Considerations
- Administer with food or milk to minimize GI side effects.
- Monitor CBC periodically; rare but serious risk of aplastic anemia; instruct to report sore throat, fever, unusual bleeding.
- Ethosuximide is the first-line drug for PURE absence epilepsy; if the patient also has generalized tonic-clonic seizures, valproate is preferred (dual coverage).
- Therapeutic drug monitoring: target serum level 40–100 mcg/mL.
Clinical Pearls
- Ethosuximide is highly specific for T-type calcium channels in the thalamus, making it uniquely effective for absence seizures — however, it is completely ineffective for any other seizure type (focal, GTC, myoclonic).
- The CHILDHOOD Absence Epilepsy study showed ethosuximide superior to both valproate and lamotrigine for cognitive outcomes in children with absence epilepsy, making it the first-line drug for this specific indication.
Safety Profile
Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.